scispace - formally typeset
X

Xihong Lin

Researcher at Harvard University

Publications -  389
Citations -  32083

Xihong Lin is an academic researcher from Harvard University. The author has contributed to research in topics: Population & Genome-wide association study. The author has an hindex of 76, co-authored 361 publications receiving 26162 citations. Previous affiliations of Xihong Lin include Texas A&M University & University of Washington.

Papers
More filters
Journal ArticleDOI

The role of choice in health education intervention trials: a review and case study.

TL;DR: Analysis of process data from a mixed RCT/preference trial comparing two formats of the "Women take PRIDE" heart disease management program indicates that being able to choose one's program format did not significantly affect the decision to participate in the study.
Journal ArticleDOI

Diuretic Therapy for Hypertension and the Risk of Primary Cardiac Arrest

TL;DR: In this paper, the association between thiazide treatment for hypertension and the occurrence of primary cardiac arrest was examined in a population-based case-control study among enrollees of a health maintenance organization.
Journal ArticleDOI

Marginal longitudinal nonparametric regression: Locality and efficiency of spline and kernel methods

TL;DR: Evidence is provided suggesting that for the marginal model, marginal smoothing and penalized regression splines are not local in their behavior, and evidence suggests that when using spline methods, it is worthwhile to account for the correlation structure.
Journal ArticleDOI

Relationship of interictal epileptiform discharges to sleep depth in partial epilepsy

TL;DR: It is suggested that processes underlying the deepening of NREM sleep may contribute to spike activation in partial epilepsy.
Journal ArticleDOI

Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer.

TL;DR: New statistical analyses of data arising from a clinical trial designed to compare two-stage dynamic treatment regimes (DTRs) for advanced prostate cancer are presented, with consideration of bivariate per-course outcomes encoding both efficacy and toxicity.